Thursday 7 May, 2026
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder that impacts patients across a broad age range…
Read morePoster: Drug/Disease Modelling - Paediatrics
TOWARD PRECISION DOSING OF CEFTRIAXONE IN CHILDREN WITH SICKLE CELL DISEASE
Thursday 7 May, 2026
Introduction: Infections are the leading cause of mortality among patients with sickle cell disease (SCD) worldwide. [1] This population is…
Read morePharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy
Thursday 7 May, 2026
Introduction: Givinostat is an oral histone deacetylase inhibitor indicated for the treatment of Duchenne muscular Dystrophy (DMD) in patients aged…
Read moreSystemic bioavailability and cortisol suppression of ocular dexamethasone in preterm infants: a PK/PD analysis
Thursday 7 May, 2026
Objectives Ocular dexamethasone is licensed as an anti-inflammatory agent for adults, while paediatric use is generally off-label and recommendations are…
Read moreMODEL-BASED META-ANALYSIS OF PARACETAMOL DOSE–RESPONSE IN PAEDIATRIC TONSILLECTOMY PAIN
Thursday 7 May, 2026
Objectives: Model-Based Meta-Analysis (MBMA) is a quantitative method that combines aggregated data from multiple randomised clinical trials (RCTs) to improve…
Read morePopulation pharmacokinetics of intravenous Ceftazidime in critically ill paediatric patients
Thursday 7 May, 2026
Introduction : Ceftazidime is a widely used antibiotic in the treatment of severe infections and cystic fibrosis (CF) in critically…
Read morePopulation Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
Thursday 7 May, 2026
Introduction: Clesrovimab (MK-1654), a monoclonal antibody with an extended half-life targeting the respiratory syncytial virus (RSV) fusion protein, is being…
Read moreModel-informed approach to Support Dose Selection for Lurbinectedin in Pediatric Patients with Advanced Solid Tumors and Recurrent/Refractory Ewing Sarcoma
Thursday 7 May, 2026
Introduction Lurbinectedin is a selective inhibitor of oncogenic transcription that has demonstrated significant clinical activity across various adult solid tumors….
Read moreQuantifying the CYP3A ontogeny in the gut wall and liver using a reduced population physiologically-based pharmacokinetic model
Thursday 7 May, 2026
Objectives: While the ontogeny of CYP3A enzymes and the difference between gut wall and hepatic maturation have been extensively studied,…
Read morePhysiologically Based Pharmacokinetic Modeling of Cefotaxime to Inform Pediatric Dosing in Renal Impairment
Thursday 7 May, 2026
Introduction: Cefotaxime is a broad spectrum, third-generation cephalosporin antibiotic prescribed for the treatment of severe infections in pediatrics (1). Renal…
Read more